AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03153826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of clinical and biological characteristics of patients
Description: Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
Study NCT02079675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI3246 Low Dose
Description: SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study NCT02079675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI3246 High Dose
Description: SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study NCT02079675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study NCT02309424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vinegar
Description: 0,50mmol vinegar (6% acetic acid)
Study NCT02309424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml water
Study NCT01118819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium novyi-NT spores
Description: Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
Study NCT01940302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LEHEL multi-nutrients supplement
Description: The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
Study NCT02938442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P10s-PADRE with MONTANIDE™ ISA 51 VG
Description: Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02938442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study NCT02389842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Taselisib / Pictilisib
Study NCT03529565 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03529565 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03529565 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00890760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly
Description: AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
Study NCT03132324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: INCB059872 tablets
Study NCT00633958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
Study NCT00633958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Study NCT04145830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Cyclo Plasty (UCP)
Description: Cyclocoagulation using High Intensity Focused Ultrasound
Study NCT00003648 — intervention group
Intervention type: GENETIC
Intervention: DNA stability analysis
Study NCT00003648 — intervention group
Intervention type: GENETIC
Intervention: gene rearrangement analysis
Study NCT03633227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: OCA will be administered per dose and schedule specified in the arm description.
Study NCT03633227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OCA matching placebo will be administered per the schedule specified in the arm description.
Study NCT06408051 — intervention group
Intervention type: PROCEDURE
Intervention: Injection of onabotulinumtoxinA into the bladder wall
Description: BTX was injected into the detrusor muscles at 20 sites
Study NCT02200952 — intervention group
Intervention type: DRUG
Intervention: recombinant LH
Description: recombinant LH twice/day for 10 days from pick up
Study NCT00076180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu-MiK-Beta-1
Description: Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
Study NCT03529565 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03071913 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study NCT01991912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open lumbar decompression
Description: A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
Study NCT00822913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical injection of Botulinum A toxin
Description: One treatment, 200 U vials diluted in 20 ml normal saline
Study NCT02989961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resticutis
Description: Autologous, Activated-Platelets type of Preparation
Study NCT02989961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resticutis
Description: Autologous, Activated-Platelets type of Preparation
Study NCT02989961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-Poor Plasma (PPP)
Description: A preparation of low platelet plasma obtained by a high-speed centrifugation step.
Study NCT02317016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291
Study NCT02317016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
Study NCT02317016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
Study NCT04111276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Osteoarthritis Brace gait fluoroscopy
Description: Gait under fluoroscopy surveillance with brace
Study NCT04111276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait fluoroscopy without brace
Description: Gait under fluoroscopy surveillance without brace
Study NCT04111276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: JointVue ultrasound
Description: JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
Study NCT04111276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer Tomography
Description: Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
Study NCT01461954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100
Description: FST-100
Study NCT01461954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FST-100 Vehicle
Description: FST-100 Vehicle
Study NCT02427594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
Study NCT02427594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet
Description: Diet without sodium bicarbonate supplementation
Study NCT02317016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - rosuvastatin
Description: Blood sampling to measure rosuvastatin levels
Study NCT02317016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study NCT03847155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: The patients will receive a nicotine patch for the period of a maximum of 7 days.
Study NCT03847155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: The patients will receive a placebo patch for the period of a maximum of 7 days.
Study NCT01556256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver-Related Intervention or Procedure
Description: Undergo TMV+P
Study NCT01556256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Undergo TMV
Study NCT01556256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Undergo TMV+P
Study NCT01556256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01556256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00890786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5.
Study NCT00890786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days).
Study NCT00890786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days).
Study NCT03518541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Derotation Osteotomy (FDO)
Description: Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
Study NCT03518541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Derotation Osteotomy (FDO)
Description: Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
Study NCT03677206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exposure to green LED light
Description: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
Study NCT03677206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure to green LED light
Description: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
Study NCT02593214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wondaleaf®
Description: Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
Study NCT04253301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnoVein Valve Treatment
Description: Subjects will have the InnoVein Valve implanted
Study NCT03472378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15
Description: Oral Solution of 4.8 mL containing 120 mg of DFN-15
Study NCT03472378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution of 4.8 mL containing 0 mg of DFN-15
Study NCT02853734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEVERE PERIODONTITIS
Description: Patients exhibiting moderate to severe periodontitis
Study NCT02853734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NO PERIODONTITIS
Description: Patients without existing periodontitis or exhibiting mild periodontitis
Study NCT04276311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Description: The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
Study NCT03677206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exposure to white LED light
Description: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
Study NCT03677206 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exposure to white LED light
Description: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
Study NCT03071913 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01755975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
Study NCT01755975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
Study NCT00639015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
Study NCT00639015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
Study NCT01843491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-PfCA
Description: Vaccine
Study NCT03012230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03012230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03012230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02920398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: turoctocog alfa pegol
Description: Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
Study NCT02920398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
Study NCT03729518 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (IMRT or IMPT)
Description: * Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling.
Study NCT01549379 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Contrast Enhanced CT scan
Description: The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
Study NCT04094064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Use of a continuous glucose monitor during study period.
Study NCT02772614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (200 mg)
Description: 200 mg powder for oral use of unlabelled BIA 3-202
Study NCT00005113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
Study NCT00889330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcaftadine
Description: 0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
Study NCT00889330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle without active, one drop in each eye at each of two visits.
Study NCT04432779 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03619876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: 125 MG/ML subcutaneous injections